5 / 32
•
At 3 months, CMR was associated with
better overall and relapse-free survival than
lesser molecular responses.
Updated results from the phase II study of
hyper-CVAD in combination with ofatumumab as
frontline therapy for adults with CD20 positive
(CD20+) acute lymphoblastic leukemia (ALL).
GC
Issa, HM Kantarjian, F Ravandi, et al
•
In this update from a phase 2 study, 53
adults with CD20-positive (CD20+)
acute lymphoblastic leukaemia (ALL)
received the combination of ofatumumab
with hyper-CVAD. Of the 50 patients
evaluable for response, 49 had complete
remission following one cycle, with 48 of
52 patients becoming negative for minimal
residual disease. A majority of patients had
febrile neutropaenia during induction and
consolidation (67% and 89%, respectively).
CR duration and overall survival rates at
2 years were 74% and 83%, respectively.
•
The researchers concluded that ofatumum-
ab with hyper-CVAD is effective and safe
in patients with CD20+ Ph− ALL.
Long-term survival of patients with therapy-
related MDS (tMDS) compared with de novo
MDS following allogeneic hematopoietic cell
transplantation (alloHCT).
AT Pham, IT Aldoss,
SM Li, et al
•
In a retrospective study, the outcomes were
compared between 264 patients who had
either therapy-induced myelodysplastic
© ASCO/Matt Herp 2016
syndrome (tMDS) or de novo MDS who
received allogeneic haematopoietic cell
transplantation (alloHCT). Patients with
tMDS were more likely to have poor-risk
karyotype than patients with de novo MDS
(63% vs 31%, respectively; P < 0.01), but
researchers did not find differences in
5-year overall survival, non-relapse mor-
tality, and relapse rates between the groups.
In patients with tMDS, more recent era of
alloHCT and younger age were associated
with improved overall survival (P < 0.01).
•
The outcomes associated with alloHCT in
patients with tMDS are similar to those in
patients with de novo MDS.
Pacritinib (PAC) vs best available therapy (BAT)
in myelofibrosis (MF): 60 week follow-up of the
phase III PERSIST-1 trial.
RA Mesa, M Egyed, A
Szoke, et al
•
In the phase 3 PERSIST-1 trial, researchers
randomised 327 patients with myelofibrosis
naive to JAK inhibitor therapy to receive
pacritinib or best available therapy. Spleen
volume stable (SVR)
≥
35% was reached in
24% of patients receiving pacritinib at 60
weeks, and 84% of patients receiving best
available therapy crossed over to pacritinib.
After crossover, SCR
≥
35% was reached in
19%. Diarrhoea associated with pacritinib
therapy was highest in the first 8 weeks
(51%). Anaemia, thrombocytopenia, and
neutropenia were also common adverse
events.
•
The conclusion drawn is that pacritinib had
no cumulative toxicity and offered durable
response in patients with myelofibrosis.
Lymphoma and chronic lymphocytic
leukaemia
Rituximab maintenance after induction with
abbreviated FCR in previously untreated
elderly (≥ 65 years) CLL patients: Results of the
randomized CLL 2007 SA trial from the French
FILO Group (NCT00645606).
C Dartigeas, E Van
Den Neste, H Maisonneuve, et al
•
Researchers randomised 409 patients aged
≥
65 years with B-cell chronic lymphocytic
leukaemia (CLL) who received induction
with four cycles of FCR to receive rituximab
or observation. Median progression-free
survival was 59.3 months with rituximab
versus 49 months with observation (P =
0.0011), and 3-year progression-free
survival and overall survival was also greater
with rituximab than observation (83% vs
64.2% and 92.6% vs 87.2%, respectively).
Improvement in progression-free survival
with rituximab was similar between
patients with or without del11q and
unmutated IGHV. Rates of haematological
and infectious toxicity were significantly
greater in patients taking rituximab than
those on observation (6.9% vs 1.9% and
18.8% vs 10.1%, respectively).
•
Progression-free survival in elderly patients
with CLL was improved with 2-year
rituximab maintenance therapy, although
rituximab was also associated with higher
toxicity.
Acalabrutinib, a second-generation bruton
tyrosine kinase (Btk) inhibitor, in previously
untreated chronic lymphocytic leukemia (CLL).
JC Byrd, JA Jones, RR Furman, et al
•
In this ongoing phase 1/2 study,
outcomes have been assessed through
December 2015 in 74 patients with
previously untreated chronic lymphocytic
leukaemia (CLL) receiving monotherapy
acalabrutinib, a Btk inhibitor. Of the
original 74 patients, 72 have continued
on acalabrutinib, with most common
adverse events being grade 1/2 headache,
diarrhoea, arthralgia, contusion, nausea,
and increased weight. Approximately half
of patients experienced treatment-related
lymphocytosis, which resolved in all but 1
patient. Partial response and stable disease
were observed in 86% and 4% of patients,
respectively.
•
Acalabrutinib was well-tolerated and has
been associated with high response rates
in patients with previously untreated CLL.
A phase 3 study has been initiated.
ASCO 2016
5
DECEMBER 2016